The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.

Details

Serval ID
serval:BIB_3E779B64CA41
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.
Journal
ESMO open
Author(s)
Sessa C., Cortes J., Conte P., Cardoso F., Choueiri T., Dummer R., Lorusso P., Ottmann O., Ryll B., Mok T., Tempero M., Comis S., Oliva C., Peters S., Tabernero J.
ISSN
2059-7029 (Electronic)
ISSN-L
2059-7029
Publication state
Published
Issued date
02/2022
Peer-reviewed
Oui
Volume
7
Number
1
Pages
100339
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The coronavirus disease-19 (COVID-19) pandemic promises to have lasting impacts on cancer clinical trials that could lead to faster patient access to new treatments. In this article, an international panel of oncology experts discusses the lasting impacts of the pandemic on oncology clinical trials and proposes solutions for clinical trial stakeholders, with the support of recent data on worldwide clinical trials collected by IQVIA. These lasting impacts and proposed solutions encompass three topic areas. Firstly, acceleration and implementation of new operational approaches to oncology trials with patient-centric, fully decentralized virtual approaches that include remote assessments via telemedicine and remote devices. Geographical differences in the uptake of remote technology, including telemedicine, are discussed in the article, focusing on the impact of the local adoption of new operational approaches. Secondly, innovative clinical trials. The pandemic has highlighted the need for new trial designs that accelerate research and limit risks and burden for patients while driving optimization of clinical trial objectives and endpoints, while testing is being minimized. Areas of considerations for clinical trial stakeholders are discussed in detail. In addition, the COVID-19 pandemic has exposed the underrepresentation of minority groups in clinical trials; the approach for oncology clinical trials to improve generalizability of efficacy and outcomes data is discussed. Thirdly, a new problem-focused collaborative framework between oncology trial stakeholders, including decision makers, to leverage and further accelerate the innovative approaches in clinical research developed during the COVID-19 pandemic. This could shorten timelines for patient access to new treatments by addressing the cultural and technological barriers to adopting new operational approaches and innovative clinical trials. The role of the different stakeholders is described, with the aim of making COVID-19 a catalyst for positive change in oncology clinical research and eventually in cancer care.
Keywords
COVID-19, Clinical Trials as Topic, Humans, Neoplasms/epidemiology, Neoplasms/therapy, Pandemics, SARS-CoV-2, Telemedicine, cancer care, clinical research, collaborative framework, real-world evidence
Pubmed
Open Access
Yes
Create date
04/01/2022 8:35
Last modification date
11/11/2022 6:39
Usage data